Letrozol Accord

Letrozole, the active ingredient in Letrozol Accord, is an aromatase inhibitor presented as an oral tablet for systemic use. It reduces estrogen production and is employed in the treatment of hormone receptor‑positive breast cancer in postmenopausal women through reversible inhibition of the aromatase enzyme.

GNH USA supplies Letrozol Accord as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres worldwide. Our distribution network ensures reliable delivery, regulatory compliance, and quality assurance for hospitals, pharmacies, and clinical trial sites across Europe, Asia, Africa, and the Americas.

Letrozole is used in endocrine therapy targeting estrogen‑dependent breast cancer.

Hormone receptor‑positive breast cancer in postmenopausal women: reduces tumor growth by lowering circulating estrogen levels. Adjuvant treatment of early‑stage hormone receptor‑positive breast cancer: helps prevent disease recurrence after surgery. Metastatic hormone receptor‑positive breast cancer in postmenopausal women: provides disease control when combined with other systemic agents.

Letrozole may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Hot flashes: sudden feeling of warmth, often with sweating. - Joint and muscle pain: aching or stiffness in muscles, joints, or limbs. - Fatigue: persistent tiredness not relieved by rest. - Nausea: mild to moderate upset stomach.

Serious or Rare Side Effects: - Severe liver injury: jaundice, elevated liver enzymes, or hepatic failure. - Bone fracture (osteoporosis): increased risk of fractures due to reduced bone mineral density. - Allergic reactions: rash, swelling, or anaphylaxis requiring immediate medical attention.

When prescribing Letrozol Accord, clinicians should consider several safety measures.

Bone health monitoring: assess bone mineral density regularly due to risk of osteoporosis. Liver function testing: evaluate hepatic enzymes before and during therapy. Cardiovascular assessment: monitor for hypertension or thromboembolic events. Pregnancy avoidance: contraindicated in pregnancy; ensure effective contraception. Drug interactions: review concomitant medications that affect estrogen levels or CYP enzymes. Store at room temperature: keep in original container, protect from moisture and direct sunlight.

Letrozol Accord can interact with other medicines, requiring attention to the level of risk.

Major Interactions (Avoid): - Estrogen‑containing hormone replacement therapy: antagonizes letrozole effect. - Tamoxifen: may reduce efficacy of letrozole when used concurrently. - Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): decrease plasma concentrations of letrozole.

Moderate Interactions (Monitor Closely): - CYP2C19 inhibitors (e.g., fluoxetine, fluconazole): may increase letrozole exposure. - Anticoagulants (e.g., warfarin): monitor INR as letrozole may affect metabolism. - Statins: observe for increased muscle toxicity.